Korean Market
OWNR
Hanmi Pharm
★

National Pension Service Becomes Major Shareholder with 10.01% Stake in Hanmi Pharm, Marginal Net Purchase

 
EXCH
Hanmi Pharm
★

Hanmi Pharm Corporate Governance Report: Governance Structure and Shareholder Protection Policies

 
EXCH
Hanmi Pharm
★★★★

Hanmi Pharm Signs $1.26B GLP2 Drug Tech Transfer Deal with Lilly - Maximizing Shareholder Value

 
EXCH
Hanmi Pharm
★

Phase 3 Clinical Trial Approved for Essential Hypertension Drug HCP1803-4: Pipeline Value Boost Expected

 
OWNR
Hanmi Pharm
★

National Pension Service reduces Hanmi Pharm stake from 10.98% to 9.91%

 
EXCH
Hanmi Pharm
★

Hanmi Pharm Signs Supply Contract for 3 Cardiovascular/Respiratory Drugs in Philippines and Malaysia (Approx. 52.7 Billion KRW)

 
PERI
Hanmi Pharm
★★★

Hanmi Pharmaceutical Reports Improved Q1 2026 Results, R&D Progress, and Shareholder Return Policy

 
OWNR
Hanmi Pharm
★

NPS Submits Report on Ownership of Specified Securities

 
EXCH
Hanmi Pharm
★

Notice of Investor Relations Event - Participation in Korea Investment & Securities NDR

 
EXCH
Hanmi Pharm
★

2026 Q1 Business Overview Presentation via Meritz Securities NDR

 
EXCH
Hanmi Pharm
★

Hanmi Pharm 1Q26 OP -9.1% YoY, NP +14.4%

 
OTHR
Hanmi Pharm
★

Hanmi Pharm Confirms Appointment of Outside Director Chae Yi-bae (Term starts Apr 29)